Skip to main content
. Author manuscript; available in PMC: 2020 Nov 9.
Published in final edited form as: Lab Invest. 2018 Jan 18;98(5):620–628. doi: 10.1038/s41374-017-0013-4

Figure 3. Anti-CXCR3 treatment reduces the frequency of CXCR3-expressing effector CD8 T cells in the SMGs and smLNs.

Figure 3.

Anti-CXCR3 antibody or IgG was i.p.-administered to 4-week-old female NOD mice 3 times weekly for 6 weeks. Flow cytometry of lymphocyte populations in the SMGs (A) and smLNs (B). Data are the average of analyses of 6–12 mice for each group.